Pharmafile Logo
Pharmafocus logo
Advanced Search

Inotuzumab ozogamicin

Showing 4 posts of 4 posts found.

FDA Priority Review for Pfizer investigational leukaemia drug

February 22, 2017
Research and Development, Sales and Marketing EMA, FDA, Inotuzumab ozogamicin, Pfizer, priority review

Pfizer has announced that its leukaemia treatment inotuzumab ozogamicin has been accepted for Priority Review by the US Food and …

News

Pfizer’s leukaemia drug beats chemotherapy in Phase III trials

June 13, 2016
Research and Development, Sales and Marketing Inotuzumab ozogamicin, Pfizer, acute lymphoblastic leukaemia

Pfizer (NYSE: PFE) has announced data from a pivotal Phase III trial for acute lymphoblastic leukaemia (ALL) drug, inotuzumab ozogamicin, …

News
Pfizer image

Two oncology successes for Pfizer

April 22, 2015
Research and Development, Sales and Marketing Cancer, FDA, Inotuzumab ozogamicin, NSCLC, Pfizer, Xalkori, oncology

Pfizer has received two boosts in oncology as Xalkori gets a new breakthrough therapy designation from the FDA, and its …

News
pfizerworld

Pfizer abandons cancer trial

May 22, 2013
Research and Development, Sales and Marketing Cancer, Inotuzumab ozogamicin, Pfizer, oncology

Pfizer’s oncology pipeline has suffered a blow with the company abandoning a Phase III study of one of its investigational …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025